Genuit Group Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Genuit Group de 29.9% y 5.2% por año respectivamente. Se prevé que el BPA crezca en un 29.3% al año. Se espera que la rentabilidad financiera sea de 10.9% en 3 años.
Información clave
29.9%
Tasa de crecimiento de los beneficios
29.3%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Building | 17.0% |
Tasa de crecimiento de los ingresos | 5.2% |
Rentabilidad financiera futura | 10.9% |
Cobertura de analistas | Good |
Última actualización | 21 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Are Genuit Group plc (LON:GEN) Investors Paying Above The Intrinsic Value?
Nov 19Genuit Group plc's (LON:GEN) Share Price Matching Investor Opinion
Nov 03Is It Too Late To Consider Buying Genuit Group plc (LON:GEN)?
Oct 16Genuit Group (LON:GEN) Has A Pretty Healthy Balance Sheet
Sep 14We Think You Can Look Beyond Genuit Group's (LON:GEN) Lackluster Earnings
Aug 21Genuit Group (LON:GEN) Is Due To Pay A Dividend Of £0.041
Aug 16Genuit Group (LON:GEN) Hasn't Managed To Accelerate Its Returns
Aug 01We Think Genuit Group (LON:GEN) Can Stay On Top Of Its Debt
May 13Genuit Group (LON:GEN) Will Pay A Larger Dividend Than Last Year At £0.083
Apr 26Be Wary Of Genuit Group (LON:GEN) And Its Returns On Capital
Apr 20Genuit Group's (LON:GEN) Dividend Will Be Increased To £0.083
Mar 15Earnings Tell The Story For Genuit Group plc (LON:GEN) As Its Stock Soars 25%
Dec 18There Are Reasons To Feel Uneasy About Genuit Group's (LON:GEN) Returns On Capital
Dec 06Genuit Group (LON:GEN) Seems To Use Debt Quite Sensibly
Oct 19Should You Investigate Genuit Group plc (LON:GEN) At UK£3.01?
Oct 05Genuit Group (LON:GEN) Has Announced A Dividend Of £0.041
Aug 18Are Genuit Group plc (LON:GEN) Investors Paying Above The Intrinsic Value?
May 20These 4 Measures Indicate That Genuit Group (LON:GEN) Is Using Debt Reasonably Well
May 05Some Investors May Be Worried About Genuit Group's (LON:GEN) Returns On Capital
Mar 22Is Now The Time To Look At Buying Genuit Group plc (LON:GEN)?
Feb 03Here's Why Genuit Group (LON:GEN) Can Manage Its Debt Responsibly
Dec 09Returns On Capital Signal Tricky Times Ahead For Genuit Group (LON:GEN)
Nov 04Why Genuit Group plc (LON:GEN) Could Be Worth Watching
Sep 21Genuit Group's (LON:GEN) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 19Investors Could Be Concerned With Genuit Group's (LON:GEN) Returns On Capital
Jul 21Does Genuit Group (LON:GEN) Have A Healthy Balance Sheet?
Jun 24A Look At The Fair Value Of Genuit Group plc (LON:GEN)
Jun 11Is There Now An Opportunity In Genuit Group plc (LON:GEN)?
May 12Returns On Capital At Genuit Group (LON:GEN) Paint A Concerning Picture
Apr 12Does Genuit Group (LON:GEN) Have A Healthy Balance Sheet?
Mar 16Calculating The Intrinsic Value Of Genuit Group plc (LON:GEN)
Feb 28Should You Think About Buying Genuit Group plc (LON:GEN) Now?
Feb 07Genuit Group's (LON:GEN) Returns On Capital Not Reflecting Well On The Business
Dec 22Is Genuit Group plc (LON:GEN) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 21When Should You Buy Genuit Group plc (LON:GEN)?
Nov 08Genuit Group (LON:GEN) Seems To Use Debt Rather Sparingly
Sep 28Genuit Group (LON:GEN) Will Want To Turn Around Its Return Trends
Aug 29Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 615 | 59 | 50 | 98 | 9 |
12/31/2025 | 585 | 52 | 50 | 93 | 9 |
12/31/2024 | 555 | 41 | 47 | 90 | 9 |
6/30/2024 | 554 | 24 | 80 | 114 | N/A |
3/31/2024 | 570 | 31 | 72 | 106 | N/A |
12/31/2023 | 587 | 39 | 63 | 98 | N/A |
9/30/2023 | 598 | 37 | 59 | 99 | N/A |
6/30/2023 | 609 | 35 | 54 | 100 | N/A |
3/31/2023 | 616 | 36 | 49 | 94 | N/A |
12/31/2022 | 622 | 37 | 43 | 87 | N/A |
9/30/2022 | 619 | 42 | 42 | 78 | N/A |
6/30/2022 | 617 | 47 | 40 | 70 | N/A |
3/31/2022 | 606 | 44 | 40 | 72 | N/A |
12/31/2021 | 594 | 41 | 40 | 75 | N/A |
9/30/2021 | 557 | 39 | 52 | 85 | N/A |
6/30/2021 | 521 | 36 | 63 | 95 | N/A |
3/31/2021 | 460 | 27 | 46 | 74 | N/A |
12/31/2020 | 399 | 19 | 28 | 53 | N/A |
9/30/2020 | 398 | 22 | 22 | 46 | N/A |
6/30/2020 | 398 | 25 | 17 | 38 | N/A |
3/31/2020 | 423 | 37 | 36 | 58 | N/A |
12/31/2019 | 448 | 50 | 55 | 77 | N/A |
9/30/2019 | 447 | 50 | 55 | 77 | N/A |
6/30/2019 | 446 | 50 | 55 | 77 | N/A |
3/31/2019 | 440 | 49 | 55 | 78 | N/A |
12/31/2018 | 433 | 49 | 55 | 79 | N/A |
9/30/2018 | 423 | 47 | 51 | 75 | N/A |
6/30/2018 | 412 | 45 | 48 | 71 | N/A |
3/31/2018 | 412 | 45 | N/A | 69 | N/A |
12/31/2017 | 412 | 45 | N/A | 68 | N/A |
6/30/2017 | 374 | 44 | N/A | 65 | N/A |
3/31/2017 | 381 | 44 | N/A | 71 | N/A |
12/31/2016 | 387 | 43 | N/A | 76 | N/A |
9/30/2016 | 421 | 42 | N/A | 77 | N/A |
6/30/2016 | 406 | 40 | N/A | 78 | N/A |
3/31/2016 | 379 | 37 | N/A | 73 | N/A |
12/31/2015 | 353 | 34 | N/A | 67 | N/A |
9/30/2015 | 341 | 35 | N/A | 62 | N/A |
6/30/2015 | 329 | 36 | N/A | 56 | N/A |
3/31/2015 | 328 | 25 | N/A | 52 | N/A |
12/31/2014 | 327 | 14 | N/A | 47 | N/A |
9/30/2014 | 322 | 11 | N/A | 48 | N/A |
6/30/2014 | 317 | 9 | N/A | 50 | N/A |
3/31/2014 | 309 | 14 | N/A | 52 | N/A |
12/31/2013 | 301 | 20 | N/A | 53 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (29.9% al año) de GEN es superior a la tasa de ahorro (2.1%).
Beneficios vs. Mercado: Se prevé que los beneficios (29.9% al año) de GEN crezcan más rápidamente que el mercado UK (14.6% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de GEN crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (5.2% al año) de GEN crezcan más rápidamente que los del mercado UK (3.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 5.2% al año) de GEN crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de GEN sea baja dentro de 3 años (10.9%).